Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons
- 1Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
- 2N.A. Semashko Public Health and Healthcare Department, F.F. Erismann Institute of Public Health, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
- 3Center of Excellence for Redox Balance Research in Cardiovascular and Metabolic Disorders, 34000 Kragujevac, Serbia
Abstract
Placental dysfunction is a major component of several pregnancy complications, particularly preeclampsia and fetal growth restriction (FGR). These disorders could be presented with different phenotypes based on abnormal placentation and inadequate maternal vascular adaptation, which are baseline mechanisms in affected pregnancies. Defective trophoblast invasion and incomplete transformation of the maternal spiral arteries may produce a high-resistance uteroplacental circulation, resulting in placental hypo-perfusion, ischemia–reperfusion injury, oxidative stress and subsequent release of factors that affect maternal endothelial function. The aim of this review is to summarize the current understanding of pro-angiogenic and anti-angiogenic factors in early placental dysfunction, with special emphasis in their biological function and molecular roles, relationship with abnormal placentation and clinical significance during pregnancy. The development of placental dysfunction is generally understood as a multifactorial and multistep process. The literature evidence most often supports the three-step process of placenta dysfunction. The angiogenic imbalance may precede the clinical presentation of preeclampsia and may also be associated with fetal growth restriction. Among currently available biomarkers, the sFlt-1/PlGF ratio has the strongest clinical evidence for risk stratification in women with suspected preeclampsia. Nevertheless, the role of angiogenic factors in the earliest stages of placental dysfunction remains incompletely defined. The major challenge is to determine whether angiogenic abnormalities can identify clinically meaningful placental dysfunction early enough to permit effective intervention. This suggests that pro-angiogenic therapeutics could be a possible option for the treatment of pre-eclampsia, but also a more specific and sensitive predictive and diagnostic tool in modern obstetrics.
Related
- Alcohol-induced placental vasculopathy reprograms the placental-fetal cardiovascular axis: angiogenic mechanisms linking maternal alcohol exposure to developmental cardiovascular programming
- Neuroprotective Role of PGC-1α Against Oxidative Stress and Mitochondrial Dysfunction in Chronic Pain Pathophysiology: A Review
- Editorial: Chronic large-vessel occlusion in cerebrovascular disease: pathophysiology, diagnosis, and therapeutic advances
- Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
BibTeX
@article{turnic2026angiogenic,
title = {{Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons}},
author = {Tamara Nikolic Turnic and Marija Aksentijevic},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27208958},
url = {https://www.mdpi.com/1422-0067/27/20/8958},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Angiogenic Imbalance in Early Placental Dysfunction: Pro- and Anti-Angiogenic Factors, Pathophysiology, Screening and Therapeutic Horizons
AU - Tamara Nikolic Turnic
AU - Marija Aksentijevic
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27208958
UR - https://www.mdpi.com/1422-0067/27/20/8958
AB - Placental dysfunction is a major component of several pregnancy complications, particularly preeclampsia and fetal growth restriction (FGR). These disorders could be presented with different phenotypes based on abnormal placentation and inadequate maternal vascular adaptation, which are baseline mechanisms in affected pregnancies. Defective trophoblast invasion and incomplete transformation of the maternal spiral arteries may produce a high-resistance uteroplacental circulation, resulting in placental hypo-perfusion, ischemia–reperfusion injury, oxidative stress and subsequent release of factors that affect maternal endothelial function. The aim of this review is to summarize the current understanding of pro-angiogenic and anti-angiogenic factors in early placental dysfunction, with special emphasis in their biological function and molecular roles, relationship with abnormal placentation and clinical significance during pregnancy. The development of placental dysfunction is generally understood as a multifactorial and multistep process. The literature evidence most often supports the three-step process of placenta dysfunction. The angiogenic imbalance may precede the clinical presentation of preeclampsia and may also be associated with fetal growth restriction. Among currently available biomarkers, the sFlt-1/PlGF ratio has the strongest clinical evidence for risk stratification in women with suspected preeclampsia. Nevertheless, the role of angiogenic factors in the earliest stages of placental dysfunction remains incompletely defined. The major challenge is to determine whether angiogenic abnormalities can identify clinically meaningful placental dysfunction early enough to permit effective intervention. This suggests that pro-angiogenic therapeutics could be a possible option for the treatment of pre-eclampsia, but also a more specific and sensitive predictive and diagnostic tool in modern obstetrics.
SN - 1422-0067
ER -